Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alan Bidgoli"'
Autor:
Yan Han, Alan Bidgoli, Brittany P. DePriest, Alejandra Méndez, Khadijeh Bijangi-Vishehsaraei, Evelio D. Perez-Albuerne, Robert A. Krance, Jamie Renbarger, Jodi L. Skiles, Sung W. Choi, Hao Liu, Sophie Paczesny
Publikováno v:
JCI Insight, Vol 8, Iss 10 (2023)
BACKGROUND Currently, no laboratory tests exist to stratify for the risk of developing sinusoidal obstruction syndrome (SOS), an early endothelial complication after hematopoietic cell transplantation (HCT). Risk biomarkers of SOS have not been verif
Externí odkaz:
https://doaj.org/article/0bce86b94c4843e7b5dc401e30206d26
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality for patients with hematological malignancies and other blood disorders. Unfortunately, acute graft-versus-host disease (aGVHD) remains a major source of mor
Externí odkaz:
https://doaj.org/article/4a3c4f2de5824a368f0fd589a4789403
Autor:
Alan Bidgoli, Brittany Paige DePriest, Maedeh Vakili Saatloo, Hua Jiang, Denggang Fu, Sophie Paczesny
Publikováno v:
Transplantation and Cellular Therapy. 28:657-666
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for many hematologic and nonhematologic disorders. Graft-versus-host-disease (GVHD) in its acute or chronic form remains the most important nonrelapse post-HCT complication.
Autor:
Brittany Paige DePriest, Hong Li, Alan Bidgoli, Lynn Onstad, Daniel Couriel, Stephanie J. Lee, Sophie Paczesny
Publikováno v:
Blood Advances. 6:2981-2986
Prognostic biomarkers used to identify likelihood of disease progression have not been identified for chronic graft-versus-host disease (cGVHD), the leading cause of late nonrelapse mortality (NRM) in survivors of allogeneic hematopoietic cell transp
Publikováno v:
Expert Rev Proteomics
INTRODUCTION: Cancer immunotherapy is a rapidly growing field with exponential advancement in engineered immune cell-based therapies. For instance, an engineered chimeric antigen receptor (CAR) can be introduced in T-cells or other immune cells and a
Autor:
Alan Bidgoli, Gloria Contreras Yametti, Sanam Shahid, Andrew C. Harris, Maria I. Cancio, Barbara Spitzer, Joseph H. Oved, Richard J. O’Reilly, Audrey Mauguen, Andromachi Scaradavou, Andrew L. Kung, Jaap-Jan Boelens, Kevin J. Curran
Publikováno v:
Transplantation and Cellular Therapy. 29:S216-S217
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality for patients with hematological malignancies and other blood disorders. Unfortunately, acute graft-versus-host disease (aGVHD) remains a major source of mor
Publikováno v:
Pediatric bloodcancer. 68(7)
Autor:
Stephanie J. Lee, Hong Li, Brittany Paige DePriest, Lynn Onstad, Sophie Paczesny, Alan Bidgoli
Publikováno v:
Transplantation and Cellular Therapy. 27:S281-S282
Publikováno v:
Pediatric Blood & Cancer. 65:e27436